-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
SOPHiA GENETICS (NASDAQ:SOPH) Vs. Allena Pharmaceuticals (NASDAQ:ALNAQ) Head to Head Survey
SOPHiA GENETICS (NASDAQ:SOPH) Vs. Allena Pharmaceuticals (NASDAQ:ALNAQ) Head to Head Survey
SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.
Valuation & Earnings
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
Get SOPHiA GENETICS alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $40.45 million | 4.06 | -$73.68 million | ($1.48) | -1.75 |
| Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
Allena Pharmaceuticals has lower revenue, but higher earnings than SOPHiA GENETICS.
Volatility and Risk
SOPHiA GENETICS has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.Analyst Ratings
This is a summary of current recommendations and price targets for SOPHiA GENETICS and Allena Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 0 | 1 | 1 | 0 | 2.50 |
| Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
SOPHiA GENETICS currently has a consensus target price of $7.00, suggesting a potential upside of 170.27%. Given SOPHiA GENETICS's higher possible upside, research analysts clearly believe SOPHiA GENETICS is more favorable than Allena Pharmaceuticals.
Profitability
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -210.25% | -39.47% | -33.12% |
| Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
Insider and Institutional Ownership
31.0% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 0.2% of Allena Pharmaceuticals shares are owned by institutional investors. 3.7% of Allena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
SOPHiA GENETICS beats Allena Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About SOPHiA GENETICS
(Get Rating)
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
About Allena Pharmaceuticals
(Get Rating)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.
索菲亞基因(納斯達克：SOPH-GET評級)和艾琳娜製藥(納斯達克：ALNAQ-GET評級)都是小盤醫療公司，但哪一家是優勢投資？我們將根據這兩家公司的盈利能力、風險、收益、分析師建議、估值、股息和機構所有權等方面的實力進行比較。
Valuation & Earnings
估值與收益
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
該表格比較了索菲亞基因公司和Allena製藥公司的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $40.45 million | 4.06 | -$73.68 million | ($1.48) | -1.75 |
| Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 索菲亞遺傳學 | 4,045萬美元 | 4.06 | -7,368萬元 | ($1.48) | -1.75 |
| Allena製藥公司 | 不適用 | 不適用 | -4,866萬元 | 不適用 | 不適用 |
Allena Pharmaceuticals has lower revenue, but higher earnings than SOPHiA GENETICS.
Allena製藥公司的收入低於索菲亞遺傳公司，但收益高於索菲亞遺傳公司。
Volatility and Risk
波動性和風險
Analyst Ratings
分析師評級
This is a summary of current recommendations and price targets for SOPHiA GENETICS and Allena Pharmaceuticals, as reported by MarketBeat.
據MarketBeat報道，這是對索菲亞遺傳學和Allena製藥公司目前的建議和價格目標的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 0 | 1 | 1 | 0 | 2.50 |
| Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 索菲亞遺傳學 | 0 | 1 | 1 | 0 | 2.50 |
| Allena製藥公司 | 0 | 0 | 0 | 0 | 不適用 |
SOPHiA GENETICS currently has a consensus target price of $7.00, suggesting a potential upside of 170.27%. Given SOPHiA GENETICS's higher possible upside, research analysts clearly believe SOPHiA GENETICS is more favorable than Allena Pharmaceuticals.
索菲亞基因目前的共識目標價為7美元，暗示潛在上漲170.27%。考慮到索菲亞基因公司更有可能的上行空間，研究分析師顯然認為索菲亞基因公司比阿萊納製藥公司更有利。
Profitability
盈利能力
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了索菲亞基因公司和Allena製藥公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -210.25% | -39.47% | -33.12% |
| Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 索菲亞遺傳學 | -210.25% | -39.47% | -33.12% |
| Allena製藥公司 | 不適用 | -287.46% | -146.58% |
Insider and Institutional Ownership
內部人與機構持股
31.0% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 0.2% of Allena Pharmaceuticals shares are owned by institutional investors. 3.7% of Allena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
索菲亞基因公司31.0%的股份由機構投資者持有。相比之下，Allena製藥公司0.2%的股份由機構投資者持有。Allena PharmPharmticals 3.7%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一隻股票有望實現長期增長。
Summary
摘要
SOPHiA GENETICS beats Allena Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
索菲亞遺傳在兩隻股票比較的10個因素中有6個擊敗了Allena PharmPharmticals。
About SOPHiA GENETICS
關於索菲亞遺傳學
(Get Rating)
(獲取評級)
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
索菲亞基因公司是一家醫療保健技術公司。該公司提供索菲亞DDM平臺，這是一個基於雲的軟件即服務平臺，用於分析數據並從多模式數據集和診斷模式中生成見解。其索菲亞DDM平臺和相關的解決方案、產品和服務被世界各地的醫院、實驗室和生物製藥所使用。索菲亞遺傳集團成立於2011年，總部設在瑞士聖蘇爾皮斯。
About Allena Pharmaceuticals
關於Allena製藥公司
(Get Rating)
(獲取評級)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Allena製藥公司是一家生物製藥公司，在美國發現、開發和商業化口服酶療法，用於治療罕見和嚴重的代謝以及腎臟疾病患者。它的主要候選產品是ALLN-346，這是一種新型的尿酸降解酶，適用於晚期慢性腎臟疾病中的高尿酸血癥和痛風患者。該公司成立於2011年，總部設在馬薩諸塞州牛頓市。2022年9月2日，Allena製藥公司根據破產法第11章向美國特拉華州地區破產法院提交了自願重組請願書。
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
接受《索菲亞遺傳學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對索菲亞遺傳學和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧